Formycon AG will be responsible for the development, registration, manufacture and supply of the product. Zydus Lifesciences Global FZE, United Arab Emirates, will handle the commercialisation of FYB206 in the defined territories of the US and Canada. Shares of Zydus Lifesciences Ltd ended at ₹920, down by ₹4.60, or 0.50%, on the BSE today, December 9.
